The clinical effect of benesco™ on reflux symptoms: A double‐blind randomized placebo‐controlled trial

Abstract Background Gastroesophageal reflux disease (GERD) is one of the most prevalent gastrointestinal diseases in the western world. Lifestyle modifications and proton pump inhibitors (PPIs) form the basis of the management of GERD. A subset of patients seeks for (natural) alternative therapies besides PPIs. benesco™ is an over‐the‐counter nutrition based on quercetin which has a presumed positive effect on esophageal barrier function. Therefore we aim to assess the effect of benesco™ on reflux symptoms. Methods We performed a double‐blind randomized placebo‐controlled trial in participants with reflux symptoms. Participants were assigned randomly (1:1) to receive 6 weeks of benesco™ (three times daily one lozenge containing 200 mg of quercetin) or placebo. The primary outcome was treatment success (≥50% reduction in Reflux Disease Questionnaire Score). Secondary outcomes included GERD‐related quality of life, reflux‐free days and nights, and participant‐reported treatment success. Key Results One hundred participants were randomized. Treatment success was seen in 18 (39%) of 46 participants in the intervention group versus 21 (47%) of 45 in the placebo group ( p = 0.468). In the intervention group 10 (1–21) reflux‐free days were reported compared to 10 (2–25) in the placebo group ( p = 0.673). In addition, 38 (34–41) versus 39 (35–42) reflux‐free nights were reported ( p = 0.409). Conclusions & Inferences In our trial benesco™ showed no significant benefit over placebo at group level.